What the trials adjudicated, and how

Nearly all of the gastrointestinal burden in this class is unpleasant and benign. A small proportion is neither, and the difficulty is that the serious events present through the same symptoms as the trivial ones. Severe and persistent upper abdominal pain, particularly pain radiating to the back and accompanied by vomiting, is not tolerability and should not be managed as tolerability. Neither is vomiting with abdominal distension and absent bowel movement. The Journal states these plainly and once, because a file about expected effects has an obligation to mark the boundary of the expected.

The dehydration pathway, which is where the real harm is

The most consequential complication of this effect profile is not any single symptom. It is the sequence in which nausea reduces fluid intake, vomiting removes more, appetite suppression removes the substantial fraction of daily fluid that arrives in food, and volume depletion follows. Reports of acute kidney injury in association with this drug class are overwhelmingly of this kind rather than a direct nephrotoxic effect.

The risk is materially higher in three situations: concurrent diuretic or renin-angiotensin blockade, hot weather or heavy exertion, and any intercurrent illness with vomiting or diarrhoea. In each, the volume reserve that would ordinarily absorb a few poor days is not there.

The management is dull and effective. Fluid intake needs to be deliberate rather than appetite-led, because appetite is precisely the signal the drug has suppressed. A person who has stopped feeling thirsty in proportion to their needs is in the same situation as a person who has stopped feeling hungry in proportion to theirs, and for the same reason. This is the single point in the file where the Journal would say the standard advice is under-emphasised rather than over-confident.¹

Gallbladder disease: drug effect, weight-loss effect, or both

In the pivotal semaglutide obesity trial, gallbladder-related disorders were reported in about two and a half per cent of the active arm against just over one per cent on placebo. Observational analyses of incretin agonists across indications have found an association with gallbladder and biliary disease, with the excess concentrated at higher doses and longer durations.²

Interpretation requires holding two facts together. Rapid weight loss by any mechanism — dietary, surgical, pharmacological — raises gallstone incidence, through reduced gallbladder emptying and altered bile composition. And these drugs both cause rapid weight loss and independently reduce gallbladder motility. A randomised comparison partially separates the two, because the placebo arm also lost weight, though much less of it.

The honest summary is that there is a real excess, that it is small in absolute terms, that some of it is attributable to the weight loss the drug is prescribed to produce, and that the proportions are not cleanly established. Right upper quadrant pain, particularly severe, post-prandial and radiating to the shoulder or back, is not a tolerability symptom and should be assessed as biliary until it is shown not to be.

Pancreatitis, with its actual numbers

Acute pancreatitis has followed this drug class since the earliest incretin products, driven initially by case reports and pharmacovigilance signals. The large randomised outcome programmes provide the best available evidence, because they adjudicated events and had comparator arms in populations with an elevated background rate. In the liraglutide cardiovascular outcome programme, adjudicated acute pancreatitis was rare and did not show the imbalance the earlier signal suggested.³

Two secondary findings from that work are useful. Asymptomatic elevations in amylase and lipase are common on treatment and are not diagnostic of pancreatitis, which means an incidental enzyme result should not by itself prompt discontinuation. And prior pancreatitis, while an exclusion in many trials, has not been shown to convert into a demonstrable recurrence signal on treatment.

The clinical marker remains what it has always been: severe, persistent epigastric pain, often radiating to the back, often with vomiting that does not settle. That presentation is not the expected effect profile of this class and should be treated as an urgent assessment rather than a titration question. The Journal reports the reassuring randomised data and declines to convert it into a statement that the event does not occur.

Ileus and obstruction: rare, and worth recognising

Labelling for this class has been updated to include intestinal obstruction and ileus following post-marketing reports. The absolute numbers are small and the signal was detected through pharmacovigilance rather than trial imbalance, which places it in the category of rare events for which randomised data will probably never be adequately powered.

Recognition matters more than incidence here, because the presentation overlaps almost exactly with the expected effect profile at its severe end: nausea, vomiting, constipation, abdominal pain. The features that distinguish it are abdominal distension, absence of flatus, vomiting that continues without relief, and a picture that worsens rather than settles over a day or two.

The Journal notes an asymmetry in how this is discussed. Coverage of the label update was extensive and often alarming; coverage of the base rate was almost absent. Both are needed. A rare event is worth knowing how to recognise and not worth reorganising a treatment decision around, and the correct response to a small absolute risk is neither dismissal nor alarm but a description precise enough to act on.⁴

When the symptom is not the molecule

Everything above assumes the vial contains the compound at the stated strength and nothing else of consequence. For licensed product that is a fair assumption. For research-grade material it is a hypothesis, and it bears directly on symptom interpretation, because a person cannot reason about tolerability if the exposure is unknown.

Three failure modes produce gastrointestinal symptoms that will be misattributed. Peptide content below the labelled figure means a person is at a lower dose than they believe, and escalating on that basis produces a larger real step than intended. Content above the labelled figure does the reverse. And bacterial endotoxin, which is not detected by any purity assay, produces systemic symptoms including nausea, chills and malaise that look nothing like a specification failure on paper.

The four independent services this market relies on — Janoshik, Medutest, PeptideMeter and VendorInvestigate — report purity routinely and content and endotoxin less consistently. Several vendors, among them WXT, SSA, CPC and SWB, now publish per-batch reports; several do not. The Journal has argued in Analytics that content and endotoxin should be standard reported fields, and the tolerability case is the strongest argument for it we know.

How the Journal reports adverse-event figures

Four conventions govern the numbers here. Incidence is quoted with the comparator arm alongside it, always, because a drug figure without a placebo figure is uninterpretable in a symptom domain with a high background rate. Figures are identified as cumulative participant incidence rather than prevalence. Where a figure comes from a pooled analysis or a post-hoc tolerability paper rather than a primary publication, we say so. And observational associations are labelled as such and never described in causal language.

Where we report practice rather than evidence — which in the management sections is most of it — the text states that the recommendation rests on mechanism or on transfer from another population. We would rather publish a short list of supported measures and a labelled longer list of reasonable ones than a single confident list that conceals the difference.

Nothing in this file is medical advice. The Journal does not diagnose, does not recommend medicines or doses, and cannot assess an individual. Several compounds discussed are sold for research use only and are not approved for human use in any jurisdiction. Symptoms that are severe, persistent or worsening warrant assessment by a clinician who can examine the person concerned.

Two files in this department are really one subject read from opposite ends. Titration is the question of how to raise a dose; tolerability is the question of whether you can. Almost every practical decision in the first six months of treatment sits at the intersection, and it is the part of the treatment course with the least evidence and the most confident advice in circulation.